

Performance Against Initiation Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial   | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Date Site Ready To Start | Date of First Patient Recruited | Reasons for delay correspond to: |
|-------|--|---|---|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|----------------------------------|
| 1     | 18/EE/0176                                 | 236637  | Daratumumab in paediatric and young adults with ALL/LL  | 20/02/2018        | 13/08/2018         | 13/08/2018        | 15/08/2018                     | 16/08/2018          | 17/08/2018               |                                 | Neither                          |
| 2     | 18/NE/0108                                 | 242365  | PP-001-1001   | 21/08/2017        | 10/07/2018         | 08/06/2018        | 19/07/2018                     | 20/07/2018          | 25/07/2018               |                                 | Neither                          |
| 3     | 18/YH/0223                                 | 243476  | Study to evaluate conjugate MenACYW vaccine in the UK infant schedule   | 14/06/2018        | 16/07/2018         | 09/07/2018        | 18/07/2018                     | 18/07/2018          | 24/09/2018               | 10/10/2018                      | Sponsor                          |
| 4     | 18/EM/0024                                 | 232898  | PARC  | 22/01/2018        | 01/08/2018         | 03/05/2018        | 10/09/2018                     | 10/09/2018          | 18/09/2018               | 23/09/2018                      | Benchmark Met                    |
| 5     | 18/EM/0112                                 | 236871  | ALL-RIC   | 26/03/2018        | 03/08/2018         | 12/06/2018        | 03/08/2018                     | 11/09/2018          | 25/09/2018               | 26/02/2019                      | Neither                          |
| 6     | 18/LO/0722                                 | 238635  | A Phase 3 study of Ozanimod as induction therapy for Crohn's Disease  | 11/04/2018        | 15/08/2018         | 30/07/2018        | 28/09/2018                     | 01/10/2018          | 01/02/2019               |                                 | Sponsor                          |
| 7     | 18/WM/0190                                 | 240027  | Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma  | 25/05/2018        | 15/08/2018         | 09/08/2018        | 20/08/2018                     | 23/08/2018          | 30/08/2018               | 11/09/2018                      | Benchmark Met                    |
| 8     | 18/SW/0050                                 | 235126  | A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC  | 02/02/2018        | 31/08/2018         | 19/04/2018        | 25/09/2018                     | 26/09/2018          | 15/10/2018               | 25/10/2018                      | Benchmark Met                    |
| 9     | 18/LO/0650                                 | 244645  | PKU Low Calorie Drink Study   | 10/04/2018        | 16/07/2018         | 21/06/2018        | 16/08/2018                     | 20/08/2018          |                          |                                 | Sponsor                          |
| 10    | 18/SW/0121                                 | 239039  | Nutrition and physical activity intervention for families with FH   | 15/06/2018        | 23/07/2018         | 08/06/2018        | 02/08/2018                     | 02/08/2018          | 16/08/2018               | 29/01/2019                      | Sponsor                          |
| 11    | 18/NW/0476                                 | 246649  | Involve-CAT   | 17/04/2018        | 10/09/2018         | 06/09/2018        | 10/09/2018                     | 27/09/2018          | 27/09/2018               | 22/10/2018                      | Benchmark Met                    |
| 12    | 18/SW/0102                                 | 233231  | The effect of plasma proteins on tissue regeneration  | 04/06/2018        | 05/09/2018         | 13/07/2018        | 05/09/2018                     | 06/09/2018          | 18/09/2018               | 07/10/2018                      | Benchmark Met                    |
| 13    | 18/WS/0137                                 | 247036  | VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC  | 25/07/2018        | 01/10/2018         | 10/09/2018        | 17/10/2018                     | 18/10/2018          | 26/10/2018               | 28/12/2018                      | NHS Provider                     |
| 14    | 18/SC/0281                                 | 245538  | AFTER study   | 11/09/2018        | 03/10/2018         | 02/07/2018        | 23/11/2018                     | 11/12/2018          | 11/12/2018               | 13/12/2018                      | NHS Provider                     |
| 15    | 18/LO/0723                                 | 244615  | RPC01-3203: study of Ozanimod as Maintenance therapy for Crohns Disease   | 11/04/2018        | 12/10/2018         | 18/09/2018        | 22/10/2018                     | 06/11/2018          | 13/03/2019               |                                 | Sponsor                          |
| 16    | 18/LO/1223                                 | 244752  | RPC01-3204: Open Label Extension study of Ozanimod for Crohn's Disease  | 11/04/2018        | 12/10/2018         | 18/09/2018        | 22/10/2018                     | 06/11/2018          | 13/03/2019               |                                 | Sponsor                          |
| 17    | 17/NE/0358                                 | 220871  | My-CRA Liquid 13 Cis Retinoic Acid  | 03/07/2018        | 15/10/2018         | 04/01/2018        | 17/10/2018                     | 18/10/2018          | 19/10/2018               | 30/11/2018                      | Benchmark Met                    |
| 18    | 17/SC/0661                                 | 227234  | Cytosponge for post-chemoradiation surveillance of oesophageal cancer   | 15/06/2018        | 15/10/2018         | 23/01/2018        | 15/10/2018                     | 30/11/2018          | 18/12/2018               |                                 | Sponsor                          |
| 19    | 16/WA/0156                                 | 204506  | UK Mini Mitral  | 07/09/2018        | 19/10/2018         | 19/07/2016        | 05/11/2018                     | 16/11/2018          | 06/12/2018               | 11/01/2019                      | Sponsor                          |
| 20    | 17/LO/1590                                 | 229278  | A Phase III Randomized Double-blind Trial of Pembrolizumab (MK-3475) (SCH-900475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Gastric or Gastroesophageal... | 24/08/2018        | 24/10/2018         | 27/10/2017        | 23/10/2018                     | 26/11/2018          | 10/01/2019               | 03/04/2019                      | Neither                          |
| 21    | 18/LO/1193                                 | 242628  | ILUMIEN IV: OPTIMAL PCI   | 02/08/2018        | 26/10/2018         | 25/10/2018        | 03/12/2018                     | 07/12/2018          | 11/12/2018               | 10/01/2019                      | Sponsor                          |
| 22    | 18/LO/1311                                 | 248599  | GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1   | 07/06/2018        | 26/10/2018         | 03/10/2018        | 24/10/2018                     | 29/10/2018          | 09/11/2018               | 24/04/2019                      | NHS Provider                     |

Performance Against Initiation Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial  | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Date Site Ready To Start | Date of First Patient Recruited | Reasons for delay correspond to: |
|-------|--|---|--|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|----------------------------------|
| 23    | 18/EM/0228                                 | 248988  | Anti-viral effect of PC786 on RSV infection in HSCT recipients                                     | 19/06/2018        | 31/10/2018         | 21/08/2018        | 02/11/2018                     | 02/11/2018          | 21/11/2018               | 16/01/2019                      | Sponsor                          |
| 24    | 18/SC/0472                                 | 234266  | ProMPT-2   | 07/09/2018        | 06/11/2018         | 24/10/2018        | 06/11/2018                     | 27/11/2018          | 11/01/2019               | 05/02/2019                      | Sponsor                          |
| 25    | 17/NI/0096                                 | 225743  | HOPE-1   | 11/10/2018        | 09/11/2018         | 14/07/2017        | 15/11/2018                     | 16/11/2018          | 26/11/2018               | 15/01/2019                      | Benchmark Met                    |
| 26    | 18/LO/0165                                 | 224726  | POLEM  | 14/09/2018        | 15/11/2018         | 09/05/2018        | 15/11/2018                     | 23/01/2019          | 28/02/2019               |                                 | Both                             |
| 27    | 18/SC/0358                                 | 230456  | Interleukin-2 Therapy of Autoimmunity in Diabetes  | 07/08/2018        | 16/11/2018         | 13/08/2018        | 11/12/2018                     | 12/12/2018          | 28/01/2019               |                                 | Sponsor                          |
| 28    | 18/LO/1238                                 | 245332  | Open Label Extension study of WVE-210201 in patients with DMD                                      | 04/10/2018        | 14/01/2019         | 25/10/2018        | 01/02/2019                     | 19/02/2019          | 07/03/2019               | 08/05/2019                      | Neither                          |
| 29    | 17/SS/0052                                 | 196827  | Early valve surgery for severe asymptomatic aortic stenosis (EVoLVeD)                              | 11/09/2018        | 27/11/2018         | 17/06/2017        | 25/02/2019                     | 25/02/2019          | 03/04/2019               | 16/04/2019                      | Sponsor                          |
| 30    | 17/SC/0536                                 | 216069  | COPELIA  | 16/10/2018        | 29/11/2018         | 04/12/2017        | 29/11/2018                     | 04/01/2019          | 18/01/2019               | 31/01/2019                      | Benchmark Met                    |
| 31    | 18/EE/0373                                 | 249396  | Breast Cancer Her 2  | 15/05/2018        | 17/01/2019         | 19/01/2019        | 22/02/2019                     | 25/02/2019          | 08/03/2019               | 16/05/2019                      | Neither                          |
| 32    | 18/LO/1450                                 | 248611  | Marigold Study 4407/0001 Marinus   | 18/10/2018        | 21/01/2019         | 07/12/2018        | 29/01/2019                     | 29/01/2019          | 06/02/2019               | 14/05/2019                      | Neither                          |
| 33    | 18/NW/0812                                 | 254035  | CAIN457M2301 (SUNSHINE): Secukinumab in hidradenitis suppurativa                                   | 02/11/2018        | 21/01/2019         | 16/01/2019        | 31/01/2019                     | 04/02/2019          | 22/02/2019               |                                 | Neither                          |
| 34    | 18/SC/0243                                 | 240684  | ORION-4  | 25/07/2018        | 04/02/2019         | 01/10/2018        | 22/02/2019                     | 28/02/2019          | 01/05/2019               | 15/05/2019                      | Sponsor                          |
| 35    | 18/SC/0016                                 | 191852  | Focus: A study to test a new treatment for dry AMD   | 19/02/2018        | 11/02/2019         | 23/04/2018        | 10/01/2019                     | 15/02/2019          | 18/02/2019               | 29/05/2019                      | Neither                          |
| 36    | 19/YH/0013                                 | 255993  | Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC                               | 11/12/2018        | 20/02/2019         | 15/02/2019        |                                |                     |                          |                                 | Sponsor                          |
| 37    | 19/EM/0003                                 | 251874  | Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy                                      | 21/12/2018        | 27/02/2019         | 20/02/2019        | 21/03/2019                     | 22/03/2019          | 22/03/2019               | 30/04/2019                      | Benchmark Met                    |
| 38    | 18/NE/0312                                 | 245315  | LTE Efficacy / Safety Study Of PF-04965842, w/wo T'cal Meds, in Subjs 12+ years with Mod to Sev AD | 27/11/2018        | 19/03/2019         | 14/12/2018        | 15/02/2019                     | 22/03/2019          |                          |                                 | Neither                          |
| 39    | 18/NW/0699                                 | 241427  | TACE-3   | 14/01/2019        | 14/05/2019         | 21/03/2019        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 40    | 18/EE/0378                                 | 248600  | Conbercept in Neovascular Age-related Macular Degeneration   | 20/11/2018        | 21/03/2019         | 10/01/2019        | 27/03/2019                     | 28/03/2019          | 18/04/2019               | 17/05/2019                      | Benchmark Met                    |
| 41    | 18/NE/0264                                 | 250542  | TRACKER  | 05/02/2019        | 25/03/2019         | 27/09/2018        | 26/03/2019                     | 27/03/2019          | 28/03/2019               |                                 | Sponsor                          |
| 42    | 18/EE/0099                                 | 239606  | CL3-95005-006 SOLSTICE   | 08/02/2019        | 01/05/2019         | 01/06/2018        | 01/05/2019                     | 03/05/2019          | 30/05/2019               | 13/06/2019                      | Benchmark Met                    |
| 43    | 19/SC/0113                                 | 241916  | Idera 2125-MEL-301   | 20/07/2017        | 30/05/2019         | 24/04/2019        | 19/06/2019                     | 19/06/2019          | 19/06/2019               | 20/06/2019                      | Benchmark Met                    |
| 44    | 18/WM/0324                                 | 246654  | FORCE - Forearm fracture Recovery in Children Evaluation   | 11/10/2018        | 14/01/2019         | 16/11/2018        | 14/01/2019                     | 04/02/2019          | 13/02/2019               | 14/02/2019                      | Benchmark Met                    |
| 45    | 18/SC/0471                                 | 242624  | Service-review and Feasibility Trial in Paediatric Weight Management                               | 11/01/2019        | 21/01/2019         | 08/11/2018        | 04/02/2019                     | 04/02/2019          |                          |                                 | Sponsor                          |
| 46    | 18/WS/0172                                 | 251636  | 1011712  | 25/09/2018        | 31/01/2019         | 03/01/2019        | 06/02/2019                     | 08/02/2019          | 27/05/2019               |                                 | Sponsor                          |
| 47    | 18/SC/0222                                 | 223737  | NeoCLEAR   | 29/11/2018        | 06/02/2019         | 12/06/2018        | 06/02/2019                     | 09/05/2019          | 09/05/2019               | 23/05/2019                      | Sponsor                          |

Performance Against Initiation Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial  | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Date Site Ready To Start | Date of First Patient Recruited | Reasons for delay correspond to: |
|-------|--|---|--|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|----------------------------------|
| 48    | 17/LO/1622                                 | 219932  | Inotuzumab Ozogamicin for treatment of pediatric BCP-ALL                                   | 23/03/2017        | 13/02/2019         | 12/02/2018        | 13/02/2019                     | 10/05/2019          | 13/05/2019               |                                 | NHS Provider                     |
| 49    | 18/SS/0010                                 | 238051  | Erdafitinib compared with Vinflunine or Docetaxel or Pembrolizumab                         | 06/03/2018        | 04/04/2019         | 21/03/2018        | 27/03/2019                     | 09/04/2019          | 10/04/2019               | 14/06/2019                      | Neither                          |
| 50    | 18/LO/0745                                 | 231612  | IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)                                     | 21/11/2018        | 08/04/2019         | 11/07/2018        | 03/05/2019                     | 09/05/2019          | 16/05/2019               |                                 | Neither                          |
| 51    | 18/SC/0242                                 | 238151  | BLING III study  | 25/06/2018        | 09/04/2019         | 24/08/2018        | 16/04/2019                     | 18/06/2019          | 24/06/2019               | 25/06/2019                      | Sponsor                          |
| 52    | 19/EM/0047                                 | 257111  | GR40306 (TENAYA): A study of faricimab in nAMD   | 05/11/2018        | 10/04/2019         | 04/04/2019        | 08/04/2019                     | 15/04/2019          | 30/04/2019               | 05/06/2019                      | Benchmark Met                    |
| 53    | 19/NI/0032                                 | 242580  | LYMRIT-37-07 - Study of safety and efficacy of Betalutin and rituximab in patients with FL | 14/01/2019        | 17/04/2019         | 01/04/2019        | 25/04/2019                     | 21/05/2019          |                          |                                 | Neither                          |
| 54    | 15/EM/0551                                 | 191168  | IRONMAN  | 04/04/2019        | 24/04/2019         | 07/07/2016        | 24/04/2019                     | 13/05/2019          | 07/06/2019               |                                 | 70 days Not yet reached          |
| 55    | 18/WA/0420                                 | 246637  | Spiroonolactone for Adult Female Acne  | 21/01/2019        | 26/04/2019         | 04/02/2019        | 30/04/2019                     | 11/06/2019          | 24/06/2019               |                                 | 70 days Not yet reached          |
| 56    | 18/LO/1187                                 | 240011  | ATHENA - a first line ovarian cancer maintenance trial.                                    | 31/07/2018        | 13/05/2019         | 11/09/2018        | 19/06/2019                     | 24/06/2019          | 27/06/2019               |                                 | 70 days Not yet reached          |
| 57    | 17/YH/0187                                 | 218853  | PRISM Trial  | 17/07/2018        | 24/05/2019         | 11/10/2017        | 24/05/2019                     | 17/06/2019          |                          |                                 | 70 days Not yet reached          |
| 58    | 18/SW/0045                                 | 239151  | Mistletoe And Breast Cancer (MAB)  | 11/06/2018        | 05/06/2019         | 02/04/2019        | 05/06/2019                     | 20/06/2019          |                          |                                 | 70 days Not yet reached          |
| 59    | 19/LO/1024                                 | 263894  | Pembrolizumab ? SBRT in Medically Inoperable Stage I/IIA NSCLC                             | 05/06/2019        | 05/06/2019         |                   |                                |                     |                          |                                 | 70 days Not yet reached          |
| 60    | 18/SS/0085                                 | 243640  | Alpha-2 agonists for sedation (A2B Trial)  | 31/05/2019        | 10/06/2019         | 14/12/2018        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 61    | 17/LO/1875                                 | 219487  | Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)                                     | 03/07/2018        | 12/06/2019         | 08/01/2018        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 62    | 19/YH/0079                                 | 259791  | Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer                       | 11/03/2019        | 13/06/2019         | 09/05/2019        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 63    | 19/NW/0106                                 | 257112  | Long-Term safety and efficacy of baricitinib - I4V-MC-JAHV                                 | 22/01/2019        | 14/06/2019         | 10/06/2019        | 04/06/2019                     | 14/06/2019          | 24/06/2019               |                                 | 70 days Not yet reached          |
| 64    | 19/SW/0028                                 | 255759  | GRAVITAS-309: Initial Treatment for Chronic Graft-Versus-Host Disease                      | 26/02/2019        | 18/06/2019         | 07/05/2019        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 65    | 19/EM/0063                                 | 253607  | AMADEUS  | 11/03/2019        | 26/06/2019         | 14/05/2019        | 26/06/2019                     |                     |                          |                                 | 70 days Not yet reached          |
| 66    | 18/LO/0555                                 | 237992  | PROTECTOR  | 07/08/2018        | 25/03/2019         | 19/04/2018        | 13/05/2019                     | 13/05/2019          | 24/06/2019               |                                 | Both                             |
| 67    | 17/EE/0213                                 | 201374  | Image guided radiotherapy and adaptive brachytherapy for cervix cancer                     | 11/01/2019        | 05/04/2019         | 09/10/2017        | 05/04/2019                     |                     |                          |                                 | Sponsor                          |
| 68    | 18/YH/0358                                 | 242342  | The Sunflower Study  | 02/10/2018        | 09/04/2019         | 12/12/2018        | 09/04/2019                     | 10/04/2019          | 10/04/2019               | 15/04/2019                      | Benchmark Met                    |

Performance Against Initiation Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial  | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Date Site Ready To Start | Date of First Patient Recruited | Reasons for delay correspond to: |
|-------|--|---|--|-------------------|--------------------|-------------------|--------------------------------|---------------------|--------------------------|---------------------------------|----------------------------------|
| 69    | 18/YH/0236                                 | 230191  | PROTHOR  | 13/03/2019        | 10/04/2019         | 17/10/2018        | 10/04/2019                     | 23/04/2019          | 24/04/2019               | 20/05/2019                      | Benchmark Met                    |
| 70    | 17/WA/0192                                 | 227541  | TAME Cardiac Arrest Trial  | 13/09/2018        | 11/04/2019         | 13/06/2018        | 15/05/2019                     | 17/05/2019          | 20/05/2019               | 20/05/2019                      | Benchmark Met                    |
| 71    | 17/SW/0250                                 | 222991  | Conventional versus minimally invasive extra-corporeal circulation                     | 26/02/2019        | 29/04/2019         | 29/11/2017        | 22/04/2019                     | 17/05/2019          | 28/05/2019               | 02/06/2019                      | Benchmark Met                    |
| 72    | 18/LO/1860                                 | 246557  | SMPaeds  | 17/04/2019        | 09/05/2019         | 02/04/2019        | 09/05/2019                     | 17/05/2019          | 04/06/2019               |                                 | 70 days Not yet reached          |
| 73    | 18/WA/0337                                 | 248818  | TIME: Take home naloxone Intervention Multi centre Emergency setting feasibility trial | 17/01/2019        | 16/05/2019         | 08/01/2019        | 16/05/2019                     | 04/06/2019          | 13/06/2019               |                                 | 70 days Not yet reached          |
| 74    | 19/YH/0050                                 | 249236  | OpTIMUM  | 08/04/2019        | 28/05/2019         | 28/03/2019        | 28/05/2019                     | 03/06/2019          | 03/06/2019               | 43642                           | Benchmark Met                    |
| 75    | 19/NW/0158                                 | 259931  | Surgery or Cast for Injuries of the Epicondyle in Children's Elbows                    | 05/06/2019        | 05/06/2019         | 25/03/2019        |                                |                     |                          |                                 | 70 days Not yet reached          |
| 76    | 18/LO/02111                                | 254025  | The FENETRE Study  | 06/06/2019        | 07/06/2019         | 25/03/2019        | 21/06/2019                     | 21/06/2019          | 22/06/2019               |                                 | 70 days Not yet reached          |
| 77    | 17/LO/1334                                 | 217338  | TOXYC: Targeted OXYgen therapy in Critical illness                                     | 16/05/2019        | 25/06/2019         | 13/11/2017        | 25/06/2019                     |                     |                          |                                 | 70 days Not yet reached          |